Vatelizumab is an immunomodulator. It binds to integrin alpha 2. It was withdrawn from Phase II trials for inflammatory bowel disease due to a lack of efficacy.
Vatelizumab is an immunomodulator. It binds to integrin alpha 2. It was withdrawn from Phase II trials for inflammatory bowel disease due to a lack of efficacy. (en)
Vatelizumab is an immunomodulator. It binds to integrin alpha 2. It was withdrawn from Phase II trials for inflammatory bowel disease due to a lack of efficacy. (en)